Literature DB >> 23306847

Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy.

Sun Young Ahn1, Hyun Seok Lee, Young Oh Kweon, Won Young Tak, Soo Young Park.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23306847     DOI： 10.1007/s10620-012-2522-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  16 in total

Review 1.  Spontaneous regression of hepatocellular carcinoma: a systematic review.

Authors:  Susana Oquiñena; Francisco Guillen-Grima; Mercedes Iñarrairaegui; Jose M Zozaya; Bruno Sangro
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-03       Impact factor: 2.566

2.  Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma.

Authors:  Marialuisa Novi; Ernesto C Lauritano; Anna C Piscaglia; Brunella Barbaro; Maria A Zocco; Maurizio Pompili; Antonio Gasbarrini
Journal:  Am J Gastroenterol       Date:  2009-05-05       Impact factor: 10.864

3.  Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.

Authors:  Tadashi Inuzuka; Hiroki Nishikawa; Akira Sekikawa; Haruhiko Takeda; Shinichiro Henmi; Azusa Sakamoto; Sumio Saito; Ryuichi Kita; Toru Kimura; Yukio Osaki; Masatoshi Kudo
Journal:  Oncology       Date:  2011-12-22       Impact factor: 2.935

Review 4.  Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.

Authors:  Masatoshi Kudo; Kazuomi Ueshima
Journal:  Oncology       Date:  2010-07-08       Impact factor: 2.935

5.  Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib.

Authors:  M Yeganeh; R S Finn; S Saab
Journal:  Am J Transplant       Date:  2009-12       Impact factor: 8.086

6.  Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.

Authors:  Sabine Irtan; Xavier Chopin-Laly; Maxime Ronot; Sandrine Faivre; Valérie Paradis; Jacques Belghiti
Journal:  Liver Int       Date:  2011-01-11       Impact factor: 5.828

7.  Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.

Authors:  Sean Xiang Wang; Abigail Byrnes; Sadhna Verma; John R Pancoast; Olivier Rixe
Journal:  Target Oncol       Date:  2010-03-23       Impact factor: 4.493

8.  Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report.

Authors:  Leonidas Chelis; Napoleon Ntinos; Vasilios Souftas; Savas Deftereos; Nikolaos Xenidis; Elen Chamalidou; Eustratios Maltezos; Stylianos Kakolyris
Journal:  Med Oncol       Date:  2010-08-31       Impact factor: 3.064

9.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

10.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245
View more
  4 in total

1.  Long-term follow-up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report.

Authors:  Jung Gil Park; Won Young Tak; Soo Young Park; Young Oh Kweon; Se Young Jang; Soo Hyun Lee; Yu Rim Lee; Sun Kyung Jang; Keun Hur; Heon Ju Lee
Journal:  Oncol Lett       Date:  2017-08-22       Impact factor: 2.967

2.  Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.

Authors:  Jung Gil Park; Soo Young Park; Hye Won Lee
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

3.  Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.

Authors:  Jung Gil Park
Journal:  Clin Mol Hepatol       Date:  2015-09-30

Review 4.  Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?

Authors:  Matthias Pinter; Wolfgang Sieghart
Journal:  Memo       Date:  2018-08-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.